Heparin-induced thrombocytopenia cost-effectiveness of therapy: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
Line 9: | Line 9: | ||
The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.<ref name="pmidPMID27793877">{{cite journal| author=Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y et al.| title=Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. | journal=Blood | year= 2016 | volume= 128 | issue= 26 | pages= 3043-3051 | pmid=PMID27793877 | doi=10.1182/blood-2016-07-728030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27793877 }} </ref> Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. | The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.<ref name="pmidPMID27793877">{{cite journal| author=Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y et al.| title=Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. | journal=Blood | year= 2016 | volume= 128 | issue= 26 | pages= 3043-3051 | pmid=PMID27793877 | doi=10.1182/blood-2016-07-728030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27793877 }} </ref> Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. | ||
<ref name="pmidPMID27793877">{{cite journal| author=Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y et al.| title=Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. | journal=Blood | year= 2016 | volume= 128 | issue= 26 | pages= 3043-3051 | pmid=PMID27793877 | doi=10.1182/blood-2016-07-728030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27793877 }} </ref> | <ref name="pmidPMID27793877">{{cite journal| author=Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y et al.| title=Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. | journal=Blood | year= 2016 | volume= 128 | issue= 26 | pages= 3043-3051 | pmid=PMID27793877 | doi=10.1182/blood-2016-07-728030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27793877 }} </ref> | ||
{| class="wikitable" | |||
! scope="col" | Characteristic/Parameter | |||
! scope="col" | '''Argatroban''' | |||
! scope="col" | '''Bivalirudin''' | |||
! scope="col" | '''Fondaparinux''' | |||
|- | |||
! scope="row" | Cost of administration | |||
| $411.43 | |||
| $411.43 | |||
| $25.40 | |||
|- | |||
! scope="row" | Average wholesale price | |||
| $1194.65 (1 vial of 250mg) | |||
| $753.07 (1 vial of 250mg) | |||
| $220.34 (1 syringe of 7.5mg) | |||
! scope="row" | Total cost for 9 days of therapy | |||
| $1326 | |||
| $1562 | |||
| $164 | |||
|} | |||
==References== | ==References== |
Revision as of 02:21, 31 July 2017
Heparin-induced thrombocytopenia |
Differentiating Heparin-induced thrombocytopenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Heparin-induced thrombocytopenia cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia cost-effectiveness of therapy |
FDA on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
CDC on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
Heparin-induced thrombocytopenia cost-effectiveness of therapy in the news |
Blogs on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Risk calculators and risk factors for Heparin-induced thrombocytopenia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]
Overview
Cost-Effectiveness of Therapy
The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.[1] Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. [1]
Characteristic/Parameter | Argatroban | Bivalirudin | Fondaparinux | ||||
---|---|---|---|---|---|---|---|
Cost of administration | $411.43 | $411.43 | $25.40 | ||||
Average wholesale price | $1194.65 (1 vial of 250mg) | $753.07 (1 vial of 250mg) | $220.34 (1 syringe of 7.5mg) | Total cost for 9 days of therapy | $1326 | $1562 | $164 |
References
- ↑ 1.0 1.1 Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y; et al. (2016). "Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States". Blood. 128 (26): 3043–3051. doi:10.1182/blood-2016-07-728030. PMID PMID27793877 Check
|pmid=
value (help).